* Ginkgo Bioworks Holdings Inc DNA.N DNA is expected
to show a
fall in quarterly revenue when it reports results on February
29 for the period ending December 31 2023
* The Boston Massachusetts-based company is expected to
report a
56.8% decrease in revenue to $42.502 million from $98.29 million
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for Ginkgo Bioworks Holdings
Inc
is for a loss of 10 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and 2 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Ginkgo
Bioworks
Holdings Inc is $2.75, above its last closing price of $1.40.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.08 -0.09 -0.16 Missed -86.7
Jun. 30 2023 -0.07 -0.08 -0.09 Missed -6.8
Mar. 31 2023 -0.09 -0.09 -0.11 Missed -22.2
Dec. 31 2022 -0.21 -0.21 -0.09 Beat 56.8
Sep. -0.30 -0.30 -0.41 Missed -38.5
30 2022
Jun. 30 2022 -0.05 -0.04 -0.43 Missed -892.4
Mar. 31 2022 -0.03 -0.03 -0.30 Missed -800.1
Dec. 31 2021 -0.04 -0.04 -0.99 Missed -2,184
.8
This summary was machine generated February 27 at 21:08 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)